Working… Menu

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01376427
Recruitment Status : Recruiting
First Posted : June 20, 2011
Last Update Posted : January 15, 2021
Information provided by (Responsible Party):
PETHEMA Foundation

Brief Summary:

This study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with ALL Bcr / Abl positive.

To determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients.

To determine whether this association can increase the rate and quality of referrals to the results of the literature of imatinib as monotherapy for elderly patients

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Ph Positive Drug: Dexamethasone Drug: Methotrexate Drug: Vincristine Not Applicable

Detailed Description:

Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day EV for 5 days (-5 to -1).

Intrathecal treatment (diagnosis and prophylactic / therapeutic) -5 days:

Methotrexate 12 mg

Systemic treatment:

  • Imatinib 400 mg daily and continuous VO.
  • Vincristine (VCR) 1 mg (absolute dose) EV 1, 8, 15 and 22.
  • Dexamethasone (DEX): 10 mg/m2 EV, IM or PO days 1-2, 8-9 days 15-16, 22-23. .

Intrathecal chemotherapy:

Triple therapy was administered with methotrexate (MTX), cytosine arabinoside (ARA-C) and hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prophase and induction):

MTX 12 mg ARA-C 40 mg Dexamethasone 4 mg

Maintenance during the first year will start after full recovery after induction and after complete reassessment of the disease (including mielograma and Bcr-Abl/Abl or Bcr-Abl/Gus ratio in peripheral blood) and will last until one year from the time of complete remission.

The basic treatment included imatinib 400 mg / day (or dasatinib), mercaptopurine at doses of 50 mg/m2 PO day and methotrexate 20 mg/m2 IM weekly.

One week every 3 months maintenance treatment added a "mini-reinduction" consisting

  • VCR: 1 mg (absolute dose), i.v., day 1.
  • Dexamethasone 40 mg / day, i.v. or p.o., days 1-2.
  • not considered more doses of triple intrathecal therapy. Reinduction only be practiced during the first year after remission, so a total of 4 quarterly.

Maintenance treatment of second year

After the first year of maintenance will perform a complete reassessment of the disease (including myelogram) and if the patient remains in complete remission maintenance will continue (without reinduction) until two years from the time of diagnosis.

Maintenance treatment of third year During the third year after complete remission imatinib administered alone (or dasatinib

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PROTOCOL TREATMENT for Acute Lymphoblastic Leukemia Ph '(BCR / ABL) POSITIVE PATIENTS AGED> 55 YEARS
Actual Study Start Date : January 2007
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Intervention Details:
  • Drug: Dexamethasone
  • Drug: Methotrexate
  • Drug: Vincristine

Primary Outcome Measures :
  1. Efficacy in terms of response rate [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Number of Participants with Adverse Events treated with chemotherapy and dasatinib combination [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Adults over 55 years diagnosed with acute lymphoblastic leukemia Ph 'positive (Bcr / Abl positive) and previously untreated

Exclusion Criteria:

  1. Other LAL negative for t (9; 22) and Bcr / Abl.
  2. biphenotypic acute leukemias or bilinear with t (9; 22).
  3. blast crisis of chronic myeloid leukemia progression during or after polychemotherapy treatment (including allo-BMT) or with inhibitors of tyrosine kinases.

    The criteria for exclusion from treatment (but not patient record) any of the following

  4. General condition affected (grades 3 and 4 WHO scale), not attributable to the LAL.
  5. Lack of consent by the patient to use their clinical d

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01376427

Layout table for location information
Hospital Germans Trias i Pujol and all Hospital Pethema Recruiting
Badalona, Barcelona, Spain
Contact: Jose Mª Ribera, Dr   
Sponsors and Collaborators
PETHEMA Foundation
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: PETHEMA Foundation Identifier: NCT01376427    
Other Study ID Numbers: LAL-07OPH
First Posted: June 20, 2011    Key Record Dates
Last Update Posted: January 15, 2021
Last Verified: January 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents